Biocompatibility of a new polycarbonate dialysis membrane.
The present report summarizes our experience with a new polycarbonate (PC)-based dialysis membrane (Gambro Lundia PRO-5) compared with a cuprophan (CP)-based membrane (Gambro Lundia 10-5N). Platelet count decreased during dialysis with CP, but was unchanged with PC membranes. Platelet injury, reflected by decreased platelet aggregation and increase in plasma beta-thromboglobulin, occurred equally with both membranes. Complement activation (C3d and C5a), leukopenia and release of granulocyte-derived elastase was more extensive with CP than with PC membranes. The new membrane represents an improvement of biocompatibility with respect to the complement-leukocyte system, whereas the effect on platelets resembles the injury caused by CP membranes.
D000244:Adenosine Diphosphate / Q000494:pharmacology; D001672:Biocompatible Materials; D002986:Clinical Trials as Topic; D003176:Complement C3 / Q000032:analysis; D015933:Complement C3d; D003182:Complement C5 / Q000032:analysis; D015936:Complement C5a; D003738:Dental Cements; D006400:Hematocrit; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000628:therapy; D007958:Leukocyte Count; D010196:Pancreatic Elastase / Q000097:blood; D010974:Platelet Aggregation / Q000187:drug effects; D010976:Platelet Count; D011076:Polycarboxylate Cement; D006435:Renal Dialysis; D001620:beta-Thromboglobulin / Q000032:analysis
D001672:Biocompatible Materials; D003176:Complement C3; D003182:Complement C5; D003738:Dental Cements; D011076:Polycarboxylate Cement; D001620:beta-Thromboglobulin; C005506:polycarbonate; D000244:Adenosine Diphosphate; D015933:Complement C3d; D015936:Complement C5a; D010196:Pancreatic Elastase